HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Drake, W M Articles by Monson, J P Search for Related Content PubMed PubMed Citation Articles by Drake, W M Articles by Monson, J P

Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant

¹ Departments of Endocrinology and ² Histopathology, St Bartholomew’s Hospital, West Smithfield, London EC1A 7BE, UK and ³ St Michael’s Hospital, Department of Laboratory Medicine and Pathobiology, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada

(Correspondence should be addressed to W M Drake; Email: w.m.drake{at}qmul.ac.uk)

Abstract

We report our findings on markers of cell proliferation (Ki-67 labelling index and topoisomerase- expression) in a somatotroph pituitary tumour before and after exposure to pegvisomant, a GH receptor antagonist developed for the treatment of acromegaly. Specimens from two separate pituitary operations, separated by a period of 17 years that included 4 years of pegvisomant treatment, were stained for markers of cellular proliferation. Ki-67 labelling index and topoisomerase- expression were both markedly greater (1–3% compared with 0–0.5% and 15–80% compared with 2–10% respectively) in the pegvisomant-exposed tumour compared with the earlier specimen. Clearly, caution must be exercised when interpreting findings from a single case, particularly one sufficiently refractory to conventional therapies to require treatment with pegvisomant. However, our data reinforce the requirement for careful radiological surveillance of the pituitary in the context of a drug that does not target the tumour responsible and where serum GH cannot serve as a marker of disease activity or tumour size.

This article has been cited by other articles:

				M Buchfelder, D Weigel, M Droste, K Mann, B Saller, K Brubach, G K Stalla, M Bidlingmaier, C J Strasburger, and on behalf of the investigators of the German Pegvi Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study Eur. J. Endocrinol., July 1, 2009; 161(1): 27 - 35. [Abstract] [Full Text] [PDF]